Published in the American Journal of Psychiatry, a King’s College London clinical trial involving the cannabis compound CBD has shown it may be beneficial in treating psychosis in schizophrenia. While cannabis can pose a risk to people with schizophrenia, this is primarily due to the effects THC, the psychoactive component that can induce paranoia, anxiety and trigger psychosis. However, CBD appears to have opposite effects.
88 patients with psychosis were administered either CBD or a placebo for six weeks in addition to any existing antipsychotic medication. Results indicate patients treated with CBD experienced a lower level of psychotic symptoms than the placebo group and these patients were more likely to have been considered “improved” by their psychiatrist. Additionally, there was indication of improvement in cognitive performance and general function without any significant side effects.